Gene therapy with BMP7 to induce tumor cell dormancy via p38MAPK activation yielded a dormancy maintenance rate of 68% (281, 282), while concurrent CXCR4 inhibition further eradicated residual dormant cells (265). This evidence concerns the gene CXCR4 and neoplasm.